In:
Movement Disorders, Wiley, Vol. 30, No. 10 ( 2015-09), p. 1426-1429
Abstract:
It has been suggested that treatment with ethyl‐eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine‐adenine‐guanine repeat numbers of 〈 45. Methods This multicenter, randomized, double‐blind, placebo‐controlled 6‐month trial compared the effects of ethyl‐EPA versus placebo on 290 subjects with mild‐to‐moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS‐4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI). Results No significant differences in TMS‐4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores. Conclusion Ethyl‐EPA was not beneficial in patients with HD during 6 months of placebo‐controlled evaluation. © 2015 International Parkinson and Movement Disorder Society
Type of Medium:
Online Resource
ISSN:
0885-3185
,
1531-8257
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2041249-6
Permalink